Director at Adicet Bio (ACET) awarded 4,200 options at $8.10 strike

Rhea-AI Filing Summary

Adicet Bio director Jeffrey Chodakewitz received a new stock option award covering 4,200 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 20, 2036. Following this grant, he holds stock options for 4,200 underlying shares.

According to the terms, the options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders after the grant date, as long as he continues serving on Adicet Bio’s board of directors.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chodakewitz Jeffrey

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	4,200	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 4,200 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 4,200 options Exercise price: $8.10 per share Expiration date: June 20, 2036 +1 more

4 metrics

Option grant size 4,200 options Stock Option (Right to Buy) granted to director

Exercise price $8.10 per share Strike price for the stock options

Expiration date June 20, 2036 Option term end date

Shares underlying options 4,200 shares Common stock underlying the options

Key Terms

Stock Option (Right to Buy), exercise price, vest in full, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 8.1000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"These shares shall vest in full on the earlier to occur"

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders following the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 04:31 PM Accepted by SEC EDGAR 06/23/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chodakewitz Jeffrey

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.1	06/21/2026		A		4,200		(1)	06/20/2036	Common Stock	4,200	$0.00	4,200	D

Explanation of Responses:

1. These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

	/s/ Nick Harvey, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Adicet Bio (ACET) disclose about Jeffrey Chodakewitz in this Form 4?

Adicet Bio reported that director Jeffrey Chodakewitz received a stock option grant for 4,200 shares at an exercise price of $8.10, expiring June 20, 2036, as part of his board compensation.

How many Adicet Bio (ACET) options did Jeffrey Chodakewitz receive?

Jeffrey Chodakewitz was granted stock options covering 4,200 shares of Adicet Bio common stock. This award brings his total reported option holdings in this filing to 4,200 underlying shares after the transaction.

What is the exercise price of Jeffrey Chodakewitz’s Adicet Bio (ACET) options?

The stock options granted to Jeffrey Chodakewitz have an exercise price of $8.10 per share. This is the price he must pay to purchase Adicet Bio common stock if he exercises the options.

When do Jeffrey Chodakewitz’s Adicet Bio (ACET) options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, provided he continues serving on Adicet Bio’s board of directors during that period.

When do the new Adicet Bio (ACET) stock options granted to Jeffrey Chodakewitz expire?

The granted stock options expire on June 20, 2036. After that date, Jeffrey Chodakewitz would no longer be able to exercise these options to purchase Adicet Bio common stock.